Advances in the Diagnosis and Management of High-Risk Cardiovascular Conditions: Biomarkers, Intracoronary Imaging, Artificial Intelligence, and Novel Anticoagulants
Open Access
- 19 January 2026
- journal article
- review article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (1) , 52
Abstract
Understanding thrombosis in acute coronary syndromes (ACSs) has evolved through advances in biomarkers, intracoronary imaging, and emerging analytical tools, improving diagnostic accuracy and risk stratification in high-risk patients. This narrative review provides an integrative overview of contemporary evidence from clinical trials, meta-analyses, and international guidelines addressing circulating biomarkers, intracoronary imaging modalities—including optical coherence tomography (OCT), intravascular ultrasound (IVUS), and near-infrared spectroscopy (NIRS)—artificial intelligence–based analytical approaches, and emerging antithrombotic therapies. High-sensitivity cardiac troponins and natriuretic peptides remain the most robust and guideline-supported biomarkers for diagnosis and prognostic assessment in ACS, whereas inflammatory markers and multimarker strategies offer incremental prognostic information but lack definitive validation for routine therapeutic guidance. Intracoronary imaging with IVUS or OCT is supported by current guidelines to guide percutaneous coronary intervention in selected patients with ACS and complex coronary lesions, leading to improved procedural optimization and clinical outcomes compared with angiography-guided strategies. Beyond procedural guidance, OCT enables detailed plaque characterization and mechanistic insights into ACS, while NIRS provides complementary information on lipid-rich plaque burden, primarily for risk stratification based on observational evidence. Artificial intelligence represents a rapidly evolving tool for integrating clinical, laboratory, and imaging data, with promising results in retrospective and observational studies; however, its clinical application in thrombosis management remains investigational due to the lack of outcome-driven randomized trials. In the therapeutic domain, factor XI inhibitors have demonstrated favorable safety profiles with reduced bleeding and preserved antithrombotic efficacy in phase II and early phase III studies, but their definitive role in ACS management awaits confirmation in large, outcome-driven randomized trials. Overall, the integration of biomarkers, intracoronary imaging, and emerging analytical and pharmacological strategies highlights the potential for more individualized cardiovascular care. Nevertheless, careful interpretation of existing evidence, rigorous validation, and alignment with guideline-directed practice remain essential before widespread clinical adoption.Keywords
Funding Information
- Postdoctoral Fellowship (88887.102383/2025-00)
This publication has 76 references indexed in Scilit:
- Artificial Intelligence for Risk Stratification of Acute Pulmonary Embolism: Perspectives on Clinical Needs, Expanding Toolkit, and Pathways ForwardThe American Journal of Cardiology, 2025
- Factor XIa inhibition as a therapeutic strategy for atherothrombosisJournal of Thrombosis and Thrombolysis, 2024
- Factor XI as a new target for prevention of thromboembolism in cardiovascular disease: a meta-analysis of randomized controlled trialsJournal of Thrombosis and Thrombolysis, 2024
- Factor XI: structure, function and therapeutic inhibitionJournal of Thrombosis and Thrombolysis, 2024
- Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA TrialsAmerican Heart Journal, 2023
- Factor XI inhibitors for the prevention of cardiovascular disease: A new therapeutic approach on the horizon?Blood Reviews, 2023
- Utility of optical coherence tomography in acute coronary syndromesCatheterization and Cardiovascular Interventions, 2023
- Biomarkers associated with coronary high-risk plaquesJournal of Thrombosis and Thrombolysis, 2022
- The Role of Intracoronary Plaque Imaging with Intravascular Ultrasound, Optical Coherence Tomography, and Near-Infrared Spectroscopy in Patients with Coronary Artery DiseaseCurrent Atherosclerosis Reports, 2016
- Assessment of Coronary Arterial Plaque by Optical Coherence TomographyThe American Journal of Cardiology, 2006